



Handwritten: Rce/1623

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Henry Lardy, et al.
Application No. : 09/675,323
5 Filed : September 28, 2000
Title : Therapeutic Treatment of Androgen Driven Conditions
Examiner : Elli Peselev
TC/A.U. : 1623

10 Docket No. : 208.3 A2
Customer No. : 26551
Confirmation No. : 2363

15 **REQUEST FOR CONTINUED EXAMINATION TRANSMITTAL**

Mail Stop RCE
Assistant Commissioner for Patents
P.O. Box 1450
20 Alexandria, VA 22313-1450

Dear Sir:

25 This is a Request for Continued Examination under 37 C.F.R. § 1.114 of the
above-identified application. A submission under 37 C.F.R. § 1.114 that consists of
amended claims, an information disclosure statement and arguments responding to the
outstanding rejections in the previous final office action accompanies this request.
Applicants request entry of the amendments to the claims and consideration of the
accompanying arguments responding to the outstanding rejections.

30 Please charge to **Deposit Account No. 501536** the \$385.00 RCE fee under 37
C.F.R. § 1.17(e) and the \$475.00 fee for extension of time under 37 C.F.R. §§ 1.136 and
1.17(a)(3) to September 5, 2004. Please charge any additional fee due or credit any
overpayment to **Deposit Account No. 501536**. Applicants hereby claim small entity
status.

Hollis-Eden Pharmaceuticals, Inc.

40 Date: 9-3-04

Phone: 858-320-2569

Handwritten signature: Daryl D. Muenchau
Daryl D. Muenchau, Reg. No. 36,616
4435 Eastgate Mall, Suite 400
San Diego, CA 92121